Metabolic syndrome in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a post hoc analyses of the EMPA-REG OUTCOME trial

BACKGROUND: Patients with type 2 diabetes (T2D) and metabolic syndrome (MetS) are at greater cardiovascular risk than those with T2D without MetS. In the current report we aim to study the characteristics, cardio-renal outcomes and the effect of empagliflozin in patients with MetS enrolled in the EM...

Descripción completa

Detalles Bibliográficos
Autores principales: Ferreira, João Pedro, Verma, Subodh, Fitchett, David, Ofstad, Anne Pernille, Lauer, Sabine, Zwiener, Isabella, George, Jyothis, Wanner, Christoph, Zinman, Bernard, Inzucchi, Silvio E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7694291/
https://www.ncbi.nlm.nih.gov/pubmed/33243221
http://dx.doi.org/10.1186/s12933-020-01174-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7694291/
https://www.ncbi.nlm.nih.gov/pubmed/33243221
http://dx.doi.org/10.1186/s12933-020-01174-6

Ejemplares similares